Mineralocorticoid receptor, CYP11B2 mRNA expression, and atrial matrix remodelling in patients with atrial fibrillation

References

• Allessie M, Ausma J, Schotten U. Electrical, contractile and structural remodeling during atrial fibrillation. Cardiovasc Res 2002; 54: 230–46.
   Google Scholar
• Spach MS. Mounting evidence that fibrosis generates a major mechanism for atrial fibrillation. Circ Res 2007; 101: 743–5.
   Google Scholar
• Healey JS, Morillo CA, Connoolly SJ. Role of the renin-angiotensin-aldosterone system in atrial fibrillation and car-diac remodeling. Curr Opin Cardiol 2005; 20: 31–7.
   Google Scholar
• Pedersen OD, Bagger H, Kober L, Torp-Pedersen C. Tran-dolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dys-function. Circulation 1999; 100: 376–80.
   Google Scholar
• Vermes E, Tardif JC, Bourassa MG, Racine N, Levesque S, White M, Guerra PG, Ducharme A. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation 2003; 107: 2926–31.
   Google Scholar
• Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahl& B, Ibsen H, Julius S, Kjeldsen SE, Lindholm LH, Nieminen MS, Devereux RB. Angiotensin II receptor block-ade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention for End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005; 45: 712–9.
   Google Scholar
• Maggioni AP, Latini R, Carson PE, Singh SN, Barlera S, Glazer R, Masson S, Cere E, Tognoni G, Cohn JN; Val-HeFT Investigators.Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 2005; 149: 548–57.
   Google Scholar
• Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, Ostergren J, Pfeffer MA, Swedberg K; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left ventric-ular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003; 362: 772–6.
   Google Scholar
• Madrid AH, Bueno MG, Rebollo JM, Marin I, Pella G, Bernal E, Rodriguez A, Cano L, Cano JM, Cabeza P, Moro C. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation 2002; 106: 331–6.
   Google Scholar
• Ueng KC, Tsai TP, Yu WC, Tsai CF, Lin MC, Chan KC, Chen CY, Wu DJ, Lin CS, Chen SA. Use of enalapril to facilitate sinus rhythm maintenance after external car-dioversion of long-standing persistent atrial fibrillation: Results of a prospective and controlled study. Eur Heart J 2003; 24: 2090–8.
   Google Scholar
• Goette A, Hoffmanns P, Enayati W, Meltendorf U, Geller JC, Klein HU. Effect of successful electrical cardioversion on serum aldosterone in patients with persistent atrial fib-rillation. Am J Cardiol 2001; 88: 906–9.
   Google Scholar
• Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005; 45: 1243–8.
   Google Scholar
• Yoshida M, Ma J, Tomita T, Morikawa N, Tanaka N, Masamura K. Mineralocorticoid receptor is overexpressed in cardiomyocytes of patients with congestive heart failure. Congest Heart Fail 2005; 11: 12–6.
   Google Scholar
• Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, PerezA, Palensky J, Wittes J. The effects of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldoctone Evaluation Study Investigators. N Engl .1 Med 1999; 341: 709–17.
   Google Scholar
• Pitt B, Remme W, Zannad F, Neaton J, Martinez F, RonikerB, Bittman R, Hurley S, Kleiman J, Gatlin M; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dys-function after myocardial infarction. N Engl J Med 2003; 348: 1309–21.
   Google Scholar
• Pei DA, Li L. Does atrial fibrillation beget atrial fibrillation? Inter J Cardiovas Dis 2006; 33: 166–9.
   Google Scholar
• van der Velden HM, van Kempen MJ, Wijffels MC, van Zijverden M, Groenewegen WA, Allessie MA, Jongsma HJ. Altered pattern of connexin 40 distribution in persistent atrial fibrillation in the goat. J Cardiovasc Electriophysiol 1998; 9: 596–607.
   Google Scholar
• Verheule S, Sato T, Everett T 4th, Engle SK, Otten D, Rubart-von der Lohe M, Nakajima HO, Nakajima H, Field U, Olgin JE. Increased vulnerability to atrial fibrilla-tion in transgenic mice with selective atrial fibrosis caused by overexpression of TGF-beta 1 . Circ Res 2004; 94: 1458–65.
   Google Scholar
• Sackner-Bernstein JD. The myocardial matrix and the development and progression of ventricular remodeling. Curr Cardiol Rep 2000; 2: 112–9.
   Google Scholar
• Everett TH 4th, Olgin JE. Atrial fibrosis and the mechanisms of atrial fibrillation. Heart Rhythm 2007; 4: S24–7.
   Google Scholar
• Rocha R, Stier CT Jr, Kifor I, Ochoa-Maya MR, Rennke HG, Williams GH, Adler GK. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 2000; 141: 3871–8.
   Google Scholar
• Satoh M, Nakamura M, Saitoh H, Satoh H, Akatsu T, Iwasaka J, Masuda T, Hiramori K. Aldosterone synthase (CYP11B2) expression and myocardial fibrosis in the failing human heart. ClM Sci (Lond) 2002; 102: 381–6.
   Google Scholar
• Jaffe IZ, Mendelsohn ME. Angiotensin II and aldosterone regulate gene transcription via functional mineralocorticoid receptor in human coronary artery smooth muscle cells. Circ Res 2005; 96: 643–50.
   Google Scholar
• Kwak SP, Patel PD, Thompson RC, Akil H, Watson SJ. 5’-Heterogeneity of the mineralocorticoid receptor for mes-senger ribonucleic acid: differential expression and regulation of splice variants within the rat hippocampus. Endocrinology 1993; 133: 2344–50.
   Google Scholar
• Zennaro MC, LeMenuet D, Lombes M. Characterization of the human mineralocorticoid receptor gene 5’-regulatory region: evidence for differential hormonal regulation of two alternative promoters via nonclassical mechanism. Mol Endocrinol 1996; 10: 1549–60.
   Google Scholar
• Schmidt BM, Schmieder RE. Aldosterone induced cardiac damage: focus on blood pressure independent effects. Am J Hypertens 2003; 16: 80–6.
   Google Scholar
• Robert V, Heymes C, Silvestre JS, Sabri A, Swynghedauw B, Delcayre C. Angiotensin AT1 receptor subtype as a cardiac target of aldosterone: role in aldosterone-salt induced fibro-sis. Hypertension 1999; 33: 981–6.
   Google Scholar
• Harada E, Yoshimura M, Yasue H, Nakagawa O, Naka-gawa M, Harada M, Mizuno Y, Nakayama M, Shimasaki Y, Ito T, Nakamura S, Kuwahara K, Saito Y, Nakao K, Ogawa H. Aldosterone induces angiotensin-converting-enzyme gene expression in cultured neonatal rat cardiocytes. Circulation 2001; 104: 137–9.
   Google Scholar
• Shroff SC, Ryu K, Martovitz NL, Hoit BD, Stambler BS. Selective aldosterone blockade suppresses atrial tachyar-rhythmias in heart failure. J Cardiovasc Electrophysiol 2006; 17: 534–41.
   Google Scholar